Source study found
Story checked
No disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up (opens in a new tab)
medicalxpress.com · 2026-10-22
Short answer
Not assessedCheck incomplete.
We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.
Share this check
The story
No disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up
medicalxpress.com · 2026-10-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Source study identified.
A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.
View article claimsThe source study
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- The study this story reportsmentioned without context
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
The Lancet · 2026
- The study this story reportspresented as the new finding
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
Evidence layer
Claim by claim
A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedIn the NICHE-2 study, none of the 111 patients in the primary efficacy population experienced disease recurrence, and all were alive at their most recent follow-up.View evidenceHide evidence
As statednone of 111 patients; all were alive
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 2 of 6Not checkedThe phase 2 NICHE-2 study investigated neoadjuvant nivolumab and ipilimumab in patients with nonmetastatic dMMR colon cancer, with two cycles of immunotherapy given over approximately four weeks before surgery.View evidenceHide evidence
As statedtwo cycles over approximately four weeks
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 3 of 6Not checkedEarlier findings showed a pathological response in 98% of patients, including a pathological complete response in 68%.View evidenceHide evidence
As stated98% pathological response; 68% pathological complete response
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 4 of 6Not checkedThe latest analysis reports a median postoperative follow-up of 58.7 months, a three-year disease-free survival rate of 100%, and an estimated five-year overall survival rate of 100%.View evidenceHide evidence
As stated58.7 months; 100% DFS at 3 years; 100% OS at 5 years
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 5 of 6Not checkedAlongside the survival analysis, the researchers found that circulating tumor DNA was detectable before treatment in most patients, and ctDNA clearance occurred in 45% after the first cycle and 82% after the second cycle among patients with baseline detectable ctDNA and available follow-up samples.View evidenceHide evidence
As stated45% after first cycle; 82% after second cycle
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 6 of 6Not checkedThe article says the findings strengthen evidence supporting neoadjuvant immunotherapy for dMMR colon cancer and raise the possibility that some patients who achieve complete response may eventually avoid surgery, though reliably identifying complete response before surgery remains a challenge.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
The Lancet · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed, Europe PMC · 39 candidate papers
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
The Lancet · 2026 · Crossref
Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.
The Lancet. Oncology · 2026 · PubMed, Crossref
637 Audit of Time to Fracture Clinic Review for Distal Radius Fractures
British Journal of Surgery · 2026 · Crossref
ALS/FTD-linked TDP-43 alterations prevent HSV-1 infection by disrupting cell-adhesion pathways
2026 · Europe PMC
Response to Letter EURJHF-25-1455
European Journal of Heart Failure · 2026 · Crossref
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.
2026 · Europe PMC
And 33 more candidates considered.